×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or “Viridian”), a biopharmaceutical company focused on discovering and developing...
2 months ago
miRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive ...
GlobeNewswire
(NASDAQ: MGEN), a development-stage biotechnology company, today announced its name change to Viridian Therapeutics, Inc. (“Viridian”).
40 months ago
Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors
Business Wire
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class...
7 months ago
Miragen Therapeutics News: Why MGEN Stock Is Skyrocketing Today
InvestorPlace
Miragen Therapeutics news of its acquisition of Viridian Therapeutics has MGEN stock skyrocketing on Wednesday.
42 months ago
Some Miragen Therapeutics (NASDAQ:MGEN) Shareholders Have Copped A Big 66% Share Price Drop
Yahoo Finance
Miragen Therapeutics isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying...
58 months ago
miRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc.
GlobeNewswire
The acquisition of Viridian was structured as a stock-for-stock transaction whereby all of Viridian's outstanding equity interests were...
42 months ago
Where are they now? Tracking down 2012's Fierce 15
Fierce Biotech
It's the 20th year we've sought out the most innovative private biotechs, which also means we've entered the second decade of checking in on...
20 months ago
miRagen begins Phase ll trial of MRG-201 for keloid
Clinical Trials Arena
miRagen Therapeutics has commenced a Phase ll clinical trial to investigate MRG-201 to treat patients with a predisposition for keloid...
70 months ago
RNA-Based Therapeutics and Vaccines Market Research Report - Forecasting Recent Developments, Emerging ...
SOUTHEAST - NEWS CHANNEL NEBRASKA
Global RNA-Based Therapeutics and Vaccines Market 2023 segmented by Manufactures (Alnylam Pharmaceuticals, Arbutus Biopharma, Arrowhead Pharmaceuticals,...
1 week ago
William Marshall: The biotech brewer - STAT
STAT
The president of miRagen Therapeutics also co-owns a craft brewery.
100 months ago